Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate for Cognitive and Behavioral Symptoms in MCI and Dementia
NCT03811847Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (6 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Feasibility of a Virtual Multicrossover Randomized Control Trial Design at 4 months. Started Nov 2019; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT03811847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03811847.